AstraZeneca has announced a historic agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients while maintaining the nation’s leadership in biopharmaceutical innovation.
At a White House event, AstraZeneca CEO Pascal Soriot joined President Trump and senior officials to confirm that the company has voluntarily met all four requests outlined in the President’s July 31 letter. The agreement enables American patients to access AstraZeneca medicines at prices aligned with those in other wealthy nations.